Collectively, both Sorafenib and Regorafenib inhibited lung metastasis of osteosarcoma by inducing PINK1 to target the lysosomal degradation of Rab22a‐NeoF1 fusion protein. This evidence concerns the gene PINK1 and osteosarcoma.